---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-061361"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:51:19.026885+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program

## Summary
- Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.
- Prioritizes ophthalmology pipeline: lead candidates SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6) for retinopathies.
- Discontinues SZN-043 in severe alcohol-associated hepatitis due to insufficient clinical benefit signal relative to development path.
- Tim Kutzkey, Ph.D. joins Board of Directors; Series A/B warrant exercise prices reduced, Series C/D warrants cancelled.
- Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies.

## SEC filing metadata
- accession: 0001193125-25-061361
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/0001193125-25-061361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/d923940d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-061361
- JSON: https://secwatch.observer/filing/0001193125-25-061361.json
- Plain text: https://secwatch.observer/filing/0001193125-25-061361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.